|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCARB1 |
Gene summary for SCARB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCARB1 | Gene ID | 949 |
| Gene name | scavenger receptor class B member 1 | |
| Gene Alias | CD36L1 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | Q8WTV0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 949 | SCARB1 | LZE7T | Human | Esophagus | ESCC | 4.72e-04 | 1.87e-01 | 0.0667 |
| 949 | SCARB1 | LZE20T | Human | Esophagus | ESCC | 6.97e-03 | 1.09e-01 | 0.0662 |
| 949 | SCARB1 | LZE22T | Human | Esophagus | ESCC | 7.08e-03 | 3.18e-01 | 0.068 |
| 949 | SCARB1 | LZE24T | Human | Esophagus | ESCC | 5.02e-03 | 1.88e-01 | 0.0596 |
| 949 | SCARB1 | P1T-E | Human | Esophagus | ESCC | 3.31e-04 | 2.51e-01 | 0.0875 |
| 949 | SCARB1 | P2T-E | Human | Esophagus | ESCC | 1.86e-68 | 1.32e+00 | 0.1177 |
| 949 | SCARB1 | P4T-E | Human | Esophagus | ESCC | 3.95e-13 | 4.31e-01 | 0.1323 |
| 949 | SCARB1 | P5T-E | Human | Esophagus | ESCC | 3.46e-16 | 3.51e-01 | 0.1327 |
| 949 | SCARB1 | P8T-E | Human | Esophagus | ESCC | 6.80e-16 | 1.22e-01 | 0.0889 |
| 949 | SCARB1 | P9T-E | Human | Esophagus | ESCC | 3.92e-08 | 1.18e-01 | 0.1131 |
| 949 | SCARB1 | P10T-E | Human | Esophagus | ESCC | 1.39e-14 | 2.22e-01 | 0.116 |
| 949 | SCARB1 | P11T-E | Human | Esophagus | ESCC | 1.87e-10 | 6.18e-01 | 0.1426 |
| 949 | SCARB1 | P12T-E | Human | Esophagus | ESCC | 3.10e-17 | 2.17e-01 | 0.1122 |
| 949 | SCARB1 | P15T-E | Human | Esophagus | ESCC | 2.77e-10 | 2.40e-01 | 0.1149 |
| 949 | SCARB1 | P16T-E | Human | Esophagus | ESCC | 3.85e-59 | 1.30e+00 | 0.1153 |
| 949 | SCARB1 | P17T-E | Human | Esophagus | ESCC | 1.85e-10 | 6.24e-01 | 0.1278 |
| 949 | SCARB1 | P19T-E | Human | Esophagus | ESCC | 1.24e-03 | 6.04e-01 | 0.1662 |
| 949 | SCARB1 | P20T-E | Human | Esophagus | ESCC | 7.11e-05 | 1.14e-01 | 0.1124 |
| 949 | SCARB1 | P21T-E | Human | Esophagus | ESCC | 1.15e-26 | 4.85e-01 | 0.1617 |
| 949 | SCARB1 | P22T-E | Human | Esophagus | ESCC | 1.30e-16 | 2.12e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001905826 | Oral cavity | EOLP | viral life cycle | 72/2218 | 317/18723 | 3.11e-08 | 1.24e-06 | 72 |
| GO:190136123 | Oral cavity | EOLP | organic cyclic compound catabolic process | 95/2218 | 495/18723 | 1.15e-06 | 2.80e-05 | 95 |
| GO:001063219 | Oral cavity | EOLP | regulation of epithelial cell migration | 62/2218 | 292/18723 | 3.09e-06 | 6.74e-05 | 62 |
| GO:004354210 | Oral cavity | EOLP | endothelial cell migration | 59/2218 | 279/18723 | 6.05e-06 | 1.19e-04 | 59 |
| GO:001063419 | Oral cavity | EOLP | positive regulation of epithelial cell migration | 41/2218 | 176/18723 | 1.45e-05 | 2.42e-04 | 41 |
| GO:004440325 | Oral cavity | EOLP | biological process involved in symbiotic interaction | 57/2218 | 290/18723 | 7.75e-05 | 9.39e-04 | 57 |
| GO:003249623 | Oral cavity | EOLP | response to lipopolysaccharide | 65/2218 | 343/18723 | 8.02e-05 | 9.65e-04 | 65 |
| GO:000223724 | Oral cavity | EOLP | response to molecule of bacterial origin | 67/2218 | 363/18723 | 1.42e-04 | 1.53e-03 | 67 |
| GO:00105957 | Oral cavity | EOLP | positive regulation of endothelial cell migration | 31/2218 | 133/18723 | 1.51e-04 | 1.62e-03 | 31 |
| GO:00105947 | Oral cavity | EOLP | regulation of endothelial cell migration | 47/2218 | 232/18723 | 1.52e-04 | 1.62e-03 | 47 |
| GO:005067317 | Oral cavity | EOLP | epithelial cell proliferation | 75/2218 | 437/18723 | 5.90e-04 | 4.97e-03 | 75 |
| GO:005170126 | Oral cavity | EOLP | biological process involved in interaction with host | 40/2218 | 203/18723 | 8.05e-04 | 6.31e-03 | 40 |
| GO:007121623 | Oral cavity | EOLP | cellular response to biotic stimulus | 46/2218 | 246/18723 | 1.10e-03 | 8.08e-03 | 46 |
| GO:00069093 | Oral cavity | EOLP | phagocytosis | 55/2218 | 308/18723 | 1.20e-03 | 8.65e-03 | 55 |
| GO:004440926 | Oral cavity | EOLP | entry into host | 31/2218 | 151/18723 | 1.50e-03 | 1.01e-02 | 31 |
| GO:005212626 | Oral cavity | EOLP | movement in host environment | 34/2218 | 175/18723 | 2.43e-03 | 1.48e-02 | 34 |
| GO:007122222 | Oral cavity | EOLP | cellular response to lipopolysaccharide | 39/2218 | 209/18723 | 2.62e-03 | 1.58e-02 | 39 |
| GO:004671826 | Oral cavity | EOLP | viral entry into host cell | 29/2218 | 144/18723 | 2.82e-03 | 1.68e-02 | 29 |
| GO:003166311 | Oral cavity | EOLP | lipopolysaccharide-mediated signaling pathway | 15/2218 | 60/18723 | 3.58e-03 | 2.03e-02 | 15 |
| GO:00157483 | Oral cavity | EOLP | organophosphate ester transport | 28/2218 | 140/18723 | 3.66e-03 | 2.05e-02 | 28 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
| hsa0414530 | Esophagus | ESCC | Phagosome | 100/4205 | 152/8465 | 3.81e-05 | 1.72e-04 | 8.82e-05 | 100 |
| hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
| hsa04145114 | Esophagus | ESCC | Phagosome | 100/4205 | 152/8465 | 3.81e-05 | 1.72e-04 | 8.82e-05 | 100 |
| hsa049796 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
| hsa049762 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
| hsa0497911 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
| hsa0497611 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
| hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
| hsa0414521 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
| hsa0516021 | Liver | HCC | Hepatitis C | 94/4020 | 157/8465 | 1.11e-03 | 4.10e-03 | 2.28e-03 | 94 |
| hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
| hsa0414531 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
| hsa0516031 | Liver | HCC | Hepatitis C | 94/4020 | 157/8465 | 1.11e-03 | 4.10e-03 | 2.28e-03 | 94 |
| hsa051608 | Oral cavity | OSCC | Hepatitis C | 103/3704 | 157/8465 | 2.17e-08 | 1.96e-07 | 9.99e-08 | 103 |
| hsa0414528 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
| hsa0516015 | Oral cavity | OSCC | Hepatitis C | 103/3704 | 157/8465 | 2.17e-08 | 1.96e-07 | 9.99e-08 | 103 |
| hsa04145113 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
| hsa0414529 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
| hsa0516024 | Oral cavity | LP | Hepatitis C | 73/2418 | 157/8465 | 1.14e-06 | 1.36e-05 | 8.74e-06 | 73 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCARB1 | SNV | Missense_Mutation | c.1234C>G | p.Pro412Ala | p.P412A | Q8WTV0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| SCARB1 | SNV | Missense_Mutation | novel | c.556C>T | p.Pro186Ser | p.P186S | Q8WTV0 | protein_coding | tolerated(0.08) | probably_damaging(0.977) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| SCARB1 | SNV | Missense_Mutation | c.652N>T | p.Leu218Phe | p.L218F | Q8WTV0 | protein_coding | deleterious(0.01) | possibly_damaging(0.856) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SCARB1 | SNV | Missense_Mutation | rs368337422 | c.133N>T | p.Arg45Cys | p.R45C | Q8WTV0 | protein_coding | tolerated(0.09) | benign(0.038) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| SCARB1 | SNV | Missense_Mutation | novel | c.989N>G | p.Asn330Ser | p.N330S | Q8WTV0 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SCARB1 | SNV | Missense_Mutation | novel | c.1182G>C | p.Met394Ile | p.M394I | Q8WTV0 | protein_coding | tolerated(1) | benign(0.001) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SCARB1 | SNV | Missense_Mutation | c.899G>T | p.Arg300Leu | p.R300L | Q8WTV0 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A6-2685-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| SCARB1 | SNV | Missense_Mutation | c.1474N>A | p.Glu492Lys | p.E492K | Q8WTV0 | protein_coding | deleterious(0.02) | probably_damaging(0.921) | TCGA-AA-A017-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SCARB1 | SNV | Missense_Mutation | novel | c.704N>G | p.Asp235Gly | p.D235G | Q8WTV0 | protein_coding | deleterious(0) | benign(0.082) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| SCARB1 | SNV | Missense_Mutation | c.280N>C | p.Tyr94His | p.Y94H | Q8WTV0 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 949 | SCARB1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | peginterferon alfa-2a | |||
| 949 | SCARB1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | ribavirin | RIBAVIRIN | ||
| 949 | SCARB1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | atorvastatin | ATORVASTATIN | 20064494 | |
| 949 | SCARB1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | fenofibrate | FENOFIBRATE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |